Long-Chain Polyunsaturated Fatty Acids Promote Paclitaxel Cytotoxicity via Inhibition of the MDR1 Gene in the Human Colon Cancer Caco-2 Cell Line

Journal of the American College of Nutrition

Volumn 30, Issue 4, 2011, Pages 265-273

  Kuan, Cheng Yi ^a   Walker, Terry H ^a   Luo, Pengju G ^c   Chen, Chin Fu ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENWOOD GENETIC CENTER   (United States)

^c Sherman College of Chiropractic   (United States)

Author keywords

Apoptosis; Fish oil; MDR1; Multidrug resistance; Paclitaxel

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; DOCOSAHEXAENOIC ACID; GLYCOPROTEIN P; ICOSAPENTAENOIC ACID; MULTIDRUG RESISTANCE PROTEIN 1; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CACO-2 CELLS; DOCOSAHEXAENOIC ACIDS; DRUG RESISTANCE, MULTIPLE; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; FISH OILS; GENE EXPRESSION REGULATION; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER;

EID: 83455246819     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2011.10719969     Document Type: Article

References (57)

1. Calviello G, Serini S, Palozza P: n-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer. Curr Signal Transduct Ther 1:255-271, 2006.
2. Riediger ND, Othman RA, Suh M, Moghadasian P: A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 109:668-679, 2009.
3. Baracos VE, Mazurak VC, Ma DW: n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 17:177-192, 2004.
4. Stehr SN, Heller AR: Omega-3 fatty acid effects on biochemical indices following cancer surgery. Clin Chim Acta 373:1-8, 2006.
5. Berquin IM, Edwards IJ, Chen YQ: Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269:363-377, 2008.
6. Biondo PD, Brindley DN, Sawyer MB, Field CJ: The potential for treatment with dietary long-chain polyunsaturated n-3 fatty acids during chemotherapy. J Nutr Biochem 19:787-796, 2008.
7. Pardini RS: Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 162:89-105, 2006.
8. Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH: Arachidonic acid-induced gene expression in colon cancer cells. Carcinogenesis 27:1950-1960, 2006.
9. Perez R, Matabosch X, Llebaria A, Balboa MA, Balsinde J: Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. J Lipid Res 47:484-491, 2006.
10. Ghosh J, Myers CE: Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 235:418-423, 1997.
11. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G: Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 36:353-362, 2008.
12. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58, 2002.
13. Borst P, Evers R, Kool M, Wijnholds J: The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357, 1999.
14. Lo YL, Huang JD: Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 59:665-672, 2000.
15. Viale M, Cordazzo C, Cosimelli B, de Totero D, Castagnola P, Aiello C, Severi E, Petrillo G, Cianfriglia M, Spinelli D: Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates. J Med Chem 52:259-266, 2009.
16. Yadav S, van Vlerken LE, Little SR, Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63:711-722, 2009.
17. Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65:3145-3167, 2008.
18. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf P: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389-398, 1998.
19. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234, 2006.
20. Assef Y, Rubio F, Colo G, del Monaco S, Costas MA, Kotsias BA: Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res 33:710-716, 2009.
21. Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R: P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 67:4915-4923, 2007.
22. Kim JY, Kajino-Sakamoto R, Omori E, Jobin C, Ninomiya-Tsuji J: Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. PLoS One 4:e4561, 2009.
23. Vasiluk L, Pinto LJ, Tsang WS, Gobas FA, Eickhoff C, Moore MM: The uptake and metabolism of benzo[a]pyrene from a sample food substrate in an in vitro model of digestion. Food Chem Toxicol 46:610-618, 2008.
24. Vidrich A, Buzan JM, Brodrick B, Ilo C, Bradley L, Fendig KS, Sturgill T, Cohn SM: Fibroblast growth factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal development. Am J Physiol Gastrointest Liver Physiol 297:G168-G178, 2009.
25. Layne KS, Goh YK, Jumpsen JA, Ryan EA, Chow P, Clandinin MT: Normal subjects consuming physiological levels of 18:3(n-3) and 20:5(n-3) from flaxseed or fish oils have characteristic differences in plasma lipid and lipoprotein fatty acid levels. J Nutr 126:2130-2140, 1996.
26. Pratt VC, Watanabe S, Bruera E, Mackey J, Clandinin MT, Baracos VE, Field CJ: Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer 87:1370-1378, 2002.
27. Hostmark AT: Serum fatty-acid albumin molar ratio and the risk of diseases. Med Hypotheses 44:539-541, 1995.
28. Assayag K, Yakunin E, Loeb V, Selkoe DJ, Sharon R: Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. Am J Pathol 171:2000-2011, 2007.
29. Ho SY, Storch J: Common mechanisms of monoacylglycerol and fatty acid uptake by human intestinal Caco-2 cells. Am J Physiol Cell Physiol 281:C1106-C1117, 2001.
30. Watanabe S, Sato T: Effects of free fatty acids on the binding of bovine and human serum albumin with steroid hormones. Biochim Biophys Acta 1289:385-396, 1996.
31. Engelbrecht AM, Toit-Kohn JL, Ellis B, ThomasM, Nell T, Smith R: Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model. Apoptosis 13:1368-1377, 2008.
32. Nano JL, Nobili C, Girard-Pipau F, Rampal P: Effects of fatty acids on the growth of Caco-2 cells. Prostaglandins Leukot Essent Fatty Acids 69:207-215, 2003.
33. van Beelen VA, Roeleveld J, Mooibroek H, Sijtsma L, Bino RJ, Bosch D, Rietjens I, Alink GM: A comparative study on the effect of algal and fish oil on viability and cell proliferation of Caco-2 cells. Food Chem Toxicol 45:716-724, 2007.
34. Essodaigui M, Broxterman HJ, Garnier-Suillerot A: Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37:2243-2250, 1998.
35. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68:1104-1109, 1993.
36. Jordan MA, Toso RJ, Thrower D, Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 90:9552-9556, 1993.
37. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996.
38. Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M: A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386:503-513, 2005.
39. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870, 2001.
40. Childs S, Yeh RL, Hui D, Ling V: Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res 58:4160-4167, 1998.
41. Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD: Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett 274:279-289, 2009.
42. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H: Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6:609-621, 2007.
43. Spratlin J, Sawyer MB: Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61:222-229, 2007.
44. Fojo T, Menefee M: Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18(suppl 5):v3-v8, 2007.
45. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995.
46. Weaver BA, Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7-12, 2005.
47. Black HS, Rhodes LE: The potential of omega-3 fatty acids in the prevention of non-melanoma skin cancer. Cancer Detect Prev 30:224-232, 2006.
48. Dupertuis YM, Meguid MM, Pichard C: Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 10:427-432, 2007.
49. Calder PC: Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52:885-897, 2008.
50. Benatti P, Peluso G, Nicolai R, Calvani M: Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr 23:281-302, 2004.
51. Russo GL: Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77:937-946, 2009.
52. Xu C, Li CY, Kong AN: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249-268, 2005.
53. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M: Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67:1954-1965, 2005.
54. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587, 2001.
55. Haslam IS, Jones K, Coleman T, Simmons NL: Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 154:246-255, 2008.
56. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306:116-120, 2003.
57. Stanley LA, Horsburgh BC, Ross J, Scheer N, Wolf CR: PXR and CAR: Nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515-597, 2006.